Stem cell products have demonstrated unique therapeutic advantages in various complex disease areas such as hematological malignancies, myocardial infarction, heart failure, Parkinson's disease, spinal cord injury, cartilage damage, and diabetes. In 2006, they successfully completed the reprogramming of somatic cells by transferring transcription factors into mouse fibroblasts, obtaining induced pluripotent stem cells (iPSC), which opened up a new path for cell therapy. In recent years, iPSC technology has developed rapidly, and its application value in scientific research and cell therapy has gradually become prominent, becoming an emerging track favored by capital.
Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') officially released the 'Blue Book on the Current Status and Future Development of the Induced Pluripotent Stem Cell (iPSC) Industry' at the '2023 Third Asian Cell and Gene Therapy Innovation Summit' on April 3, 2023 (hereinafter referred to as the 'Blue Book'). It deeply analyzes multiple dimensions such as iPSC technology development, application fields, current development status, clinical progress, capital interest, and industry pattern. The aim is to track the development context of the industry and technology, explore the potential for industry development, and analyze the driving factors behind market development. It is hoped that this will help participants in the iPSC industry sort out the current industry status and reflect future growth trends.
